Answers are grounded in this paper and cite their sources.
Keloids are fibroproliferative skin disorders with limited therapeutic options. Epigenetic regulation, particularly N6-methyladenosine (m6A) modification, along with inflammatory signaling, is increasingly implicated in their pathogenesis. By analyzing three keloid expression datasets (GSE151464, GSE212954, GSE188952), we identified regulator of G-protein signaling 1 (RGS1) as a consistently upregulated target. Both RGS1 and the m6A methyltransferase METTL3 were significantly elevated in clinical keloid tissues and primary fibroblasts, showing a positive correlation. MeRIP-qPCR confirmed abundant m6A modifications on RGS1 mRNA. Silencing METTL3 reduced m6A modification and stability of RGS1 mRNA, whereas RGS1 overexpression did not alter METTL3 levels. In keloid fibroblasts, RGS1 overexpression activated the NF-κB pathway, enhanced the secretion of IL-1β, TNF-α, and IL-6, elevated reactive oxygen species (ROS), and suppressed antioxidant proteins NQO1 and HO-1. These effects were reversed by pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor. METTL3 knockdown also impaired fibroblast proliferation, migration, invasion, and reduced fibrosis markers α-SMA, Vimentin, and COL1, all rescued by RGS1 overexpression. In a xenograft model, RGS1 overexpression accelerated lesion growth and systemic inflammation, which PDTC treatment attenuated. In summary, METTL3-mediated m6A modification stabilizes RGS1 mRNA, promoting keloid progression through NF-κB-dependent inflammation and oxidative stress, highlighting the METTL3/RGS1/NF-κB axis as a promising therapeutic target.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: